NASDAQ:UROV - Urovant Sciences Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $16.17
  • Forecasted Upside: 0.60 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$16.07
▲ +0.03 (0.19%)
1 month | 3 months | 12 months
Get New Urovant Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for UROV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for UROV

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$16.17
▲ +0.60% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Urovant Sciences in the last 3 months. The average price target is $16.17, with a high forecast of $16.25 and a low forecast of $16.00. The average price target represents a 0.60% upside from the last price of $16.07.
Hold
The current consensus among 3 contributing investment analysts is to hold stock in Urovant Sciences. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/8/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/6/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/5/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/29/2020

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/16/2020HC WainwrightReiterated RatingBuy ➝ Neutral$16.25Low
i
Rating by Ram Selvaraju at HC Wainwright
11/16/2020HC WainwrightDowngradeBuy ➝ Neutral$16.25Low
i
Rating by Ram Selvaraju at HC Wainwright
11/16/2020JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$16.00Low
i
11/16/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$16.00Low
i
11/13/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$16.25High
i
6/19/2020HC WainwrightLower Price TargetBuy$33.00 ➝ $28.00High
i
Rating by Ram Selvaraju at HC Wainwright
6/10/2020HC WainwrightReiterated RatingBuyHigh
i
Rating by Ram Selvaraju at HC Wainwright
12/31/2019HC WainwrightBoost Price TargetBuy$28.00 ➝ $33.00High
i
Rating by Ram Selvaraju at HC Wainwright
10/21/2019HC WainwrightSet Price TargetBuy$28.00Low
i
Rating by Ram Selvaraju at HC Wainwright
9/9/2019HC WainwrightReiterated RatingBuy$28.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
6/24/2019HC WainwrightSet Price TargetBuy$28.00Low
i
Rating by Ram Selvaraju at HC Wainwright
6/14/2019JPMorgan Chase & Co.Set Price TargetBuy$24.00Low
i
Rating by Eric Joseph at JPMorgan Chase & Co.
3/22/2019HC WainwrightReiterated RatingBuy$28.00Medium
i
Rating by R. Selvaraju at HC Wainwright
3/15/2019SunTrust BanksInitiated CoverageBuy ➝ Buy$24.00High
i
3/11/2019HC WainwrightInitiated CoverageBuy ➝ Buy$28.00Medium
i
Rating by R. Selvaraju at HC Wainwright
10/22/2018CowenInitiated CoverageOutperform$25.00Low
i
10/22/2018Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$19.00Low
i
10/22/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$21.00Low
i
(Data available from 11/29/2015 forward)
Urovant Sciences logo
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.
Read More

Today's Range

Now: $16.07
$15.96
$16.07

50 Day Range

MA: $10.46
$7.39
$16.19

52 Week Range

Now: $16.07
$6.55
$16.25

Volume

129,288 shs

Average Volume

133,011 shs

Market Capitalization

$508.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25